Humacyte Q2: Symvess sales up, net loss $36.8M; V012 Phase 3 hits primary endpoint

Humacyte, Inc.

Q2 2026 Symvess sales $0.4M vs $0.1M prior year; net loss $36.8M vs $37.7M.
V012 Phase 3 interim: ATEV beat AV fistula, 91 more catheter-free days (p=0.0007), infections 6 vs 23/100 pt-yrs.
Plans sBLA for dialysis access with FDA in H2 2026; FDA accepted IND for CTEV in CABG, Phase 2a expected Q3 2026.
Raised $57.5M gross in June public offering; restructuring cuts ~45 staff, saving ~$14.3M in 2026.
Cash $80.3M at 6/30/26; six-month net loss $54.4M vs net income $1.5M year ago.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.